文献速递心脑血管急症重症综合管理与镇静镇痛

左西孟旦用于心脏术后血流动力学支持

Levosimendan for Hemodynamic Support after Cardiac Surgery.
PubMed 文献 · N Engl J Med · 2017-03-21
一句话结论心脏术后需围术期血流动力学支持的患者中,左西孟旦联合标准治疗较安慰剂未降低30天死亡率(12.9% vs 12.8%)。

这项多中心、随机、双盲、安慰剂对照试验纳入心脏术后按预设标准需围术期血流动力学支持的患者,随机接受左西孟旦持续输注(0.025–0.2 μg/kg/min,至多48小时或至ICU出院)或安慰剂,并联合标准治疗。因无效在纳入506例后终止:左西孟旦组248例、安慰剂组258例。30天死亡率两组无显著差异(12.9% vs 12.8%;绝对风险差0.1个百分点,95%CI -5.7至5.9;P=0.97),机械通气时间、ICU停留时间、住院时间及低血压或心律失常发生率亦无显著差异。

要点

  • 心脏术后需围术期血流动力学支持者,左西孟旦较安慰剂未降低30天死亡率(12.9% vs 12.8%;绝对风险差0.1个百分点,95%CI -5.7至5.9;P=0.97)。
  • 试验因无效在纳入506例后终止,左西孟旦组248例、安慰剂组258例。
  • 机械通气时间中位数19小时 vs 21小时(中位数差-2小时,95%CI -5至1;P=0.48),无显著差异。
  • ICU停留时间中位数72小时 vs 84小时(中位数差-12小时,95%CI -21至2;P=0.09),无显著差异。
  • 住院时间中位数14天 vs 14天(中位数差0天,95%CI -1至2;P=0.39),低血压或心律失常发生率两组无显著差异。

适用人群与场景

  • 心脏术后按预设标准需围术期血流动力学支持的患者。

处置流程与药物剂量

  • 左西孟旦持续输注0.025–0.2 μg/kg/min,至多48小时或至ICU出院,联合标准治疗。

研究设计与关键结果

  • 多中心、随机、双盲、安慰剂对照试验,因无效在纳入506例后终止;左西孟旦组248例、安慰剂组258例。
  • 30天死亡率:左西孟旦组32例(12.9%)vs 安慰剂组33例(12.8%);绝对风险差0.1个百分点(95%CI -5.7至5.9;P=0.97),无显著差异。
  • 机械通气时间中位数:左西孟旦组19小时 vs 安慰剂组21小时;中位数差-2小时(95%CI -5至1;P=0.48),无显著差异。
  • ICU停留时间中位数:左西孟旦组72小时 vs 安慰剂组84小时;中位数差-12小时(95%CI -21至2;P=0.09),无显著差异。
  • 住院时间中位数:左西孟旦组14天 vs 安慰剂组14天;中位数差0天(95%CI -1至2;P=0.39),无显著差异。
  • 低血压或心律失常发生率两组无显著差异。

证据类型、等级与局限

  • 证据类型:多中心、随机、双盲、安慰剂对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对心脏术后按预设标准需围术期血流动力学支持的患者,加用低剂量左西孟旦较安慰剂未降低30天死亡率,原文结论为左西孟旦联合标准治疗未带来更低的30天死亡率。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Acute left ventricular dysfunction is a major complication of cardiac surgery and is associated with increased mortality. Meta-analyses of small trials suggest that levosimendan may result in a higher rate of survival among patients undergoing cardiac surgery.

METHODS: We conducted a multicenter, randomized, double-blind, placebo-controlled trial involving patients in whom perioperative hemodynamic support was indicated after cardiac surgery, according to prespecified criteria. Patients were randomly assigned to receive levosimendan (in a continuous infusion at a dose of 0.025 to 0.2 μg per kilogram of body weight per minute) or placebo, for up to 48 hours or until discharge from the intensive care unit (ICU), in addition to standard care. The primary outcome was 30-day mortality.

RESULTS: The trial was stopped for futility after 506 patients were enrolled. A total of 248 patients were assigned to receive levosimendan and 258 to receive placebo. There was no significant difference in 30-day mortality between the levosimendan group and the placebo group (32 patients [12.9%] and 33 patients [12.8%], respectively; absolute risk difference, 0.1 percentage points; 95% confidence interval [CI], -5.7 to 5.9; P=0.97). There were no significant differences between the levosimendan group and the placebo group in the durations of mechanical ventilation (median, 19 hours and 21 hours, respectively; median difference, -2 hours; 95% CI, -5 to 1; P=0.48), ICU stay (median, 72 hours and 84 hours, respectively; median difference, -12 hours; 95% CI, -21 to 2; P=0.09), and hospital stay (median, 14 days and 14 days, respectively; median difference, 0 days; 95% CI, -1 to 2; P=0.39). There was no significant difference between the levosimendan group and the placebo group in rates of hypotension or cardiac arrhythmias.

CONCLUSIONS: In patients who required perioperative hemodynamic support after cardiac surgery, low-dose levosimendan in addition to standard care did not result in lower 30-day mortality than placebo. (Funded by the Italian Ministry of Health; CHEETAH ClinicalTrials.gov number, NCT00994825 .).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Landoni G, Lomivorotov VV, Alvaro G, et al. Levosimendan for Hemodynamic Support after Cardiac Surgery. N Engl J Med. 2017. PMID: 28320259. doi:10.1056/NEJMoa1616325

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。